MedTrace Logo

Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

NCT00004825 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism.

II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population.

III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.

Conditions

  • Hyperinsulinism

Interventions

DRUG

recombinant human insulin-like growth factor I

Sponsors & Collaborators

Principal Investigators

  • Pinchas Cohen · Children's Hospital of Philadelphia

Study Design

Purpose
TREATMENT

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-05-31
Completion
1998-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004825 on ClinicalTrials.gov